Canada: Patent

Subscribe
Intellectual property law and copyright law thought leadership, articles, podcasts, videos and webinars from expert sources across the legal world. Explore insights covering topics such as licensing and syndication, patent law, trade secrets and trademark law.
Article
Patentability And The Supreme Court: Conundrums Surrounding Methods Of Medical Treatment
The Supreme Court of Canada is poised to address a fundamental question in patent law: whether methods of medical treatment constitute patentable subject matter under the Patent Act. This analysis examines the statutory framework, historical precedents, and legislative changes that have shaped Canadian patent law's approach to medical innovations, particularly in light of the repeal of former restrictions and international trade agreements.
Canada IP
GW
Gowling WLG
Article
CIPO Releases 2025 SME Roundtables Report
The Canadian Intellectual Property Office has released findings from roundtable discussions with 53 small and medium-sized businesses across six cities, revealing significant challenges in protecting intellectual property. Business owners identified cost, slow timelines, complexity, and limited knowledge as major barriers to accessing IP protection in Canada. CIPO plans to use this feedback to shape its upcoming business strategy and has already initiated a review of its fee structure.
Canada IP
OW
Oyen Wiggs Green & Mutala LLP
Article
Same Defence, Better Facts: Federal Court Allows Amendments To Bolster Prior Use Allegation
The Federal Court in Kobold Corporation v NCS Multistage Inc. addressed whether a defendant could amend its pleadings to strengthen a prior use defence after losing a summary judgment motion on that same defence. The decision clarifies the scope of the 'best foot forward' principle and distinguishes between summary judgment motions and summary trials in patent litigation.
Canada IP
MT
McCarthy Tétrault LLP
Article
Le problème des DIN dormants au Canada : comment le statut de commercialisation sape les protections de la PI pharmaceutique prévues à l’ACEUM
Le Canada a ratifié l'Accord Canada–États-Unis–Mexique avec un engagement envers un cadre de propriété intellectuelle stable pour l'innovation pharmaceutique. Cependant, le traitement des numéros d'identification de médicament (DIN) « dormants » crée une incertitude réglementaire qui lie les protections de PI au statut de commercialisation plutôt qu'à l'approbation réglementaire. Cette approche soulève des questions sur la con
Canada Healthcare
MT
McCarthy Tétrault LLP
See more

Latest Videos

See more